January 1964 in “OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)” CXCL7 is essential for muscle repair by aiding early neutrophil infiltration.
January 1987 in “Toxicological sciences” SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe symptoms and organ damage in mice.
19 citations
,
May 2018 in “Molecular Medicine Reports” miR‑339‑5p can slow down hair follicle stem cell differentiation by targeting DLX5.
4 citations
,
May 2022 in “Genes & Diseases” 2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
9 citations
,
May 2014 in “BMC medical genetics” A woman with a unique syndrome similar to TRPS has a genetic change near the TRPS1 gene, affecting its regulation.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
August 2013 in “Nature Reviews Drug Discovery” New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.
October 2018 in “Annals of Reviews & Research” The new gel provides faster and longer-lasting pain relief than the cream.
45 citations
,
January 2010 in “Journal of Veterinary Medical Science” A gene mutation causes curly hair and hair loss in rats.
1 citations
,
December 2011 in “Arzneimittelforschung” CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.
161 citations
,
August 2013 in “Journal of experimental botany” Certain inhibitors slow down plant growth by causing early cell specialization without changing the cell development pattern.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
7 citations
,
June 2010 in “Bioorganic & medicinal chemistry letters” Two new compounds were found to effectively reduce hair growth in mice.
7 citations
,
February 2023 in “Exploration of Medicine” Drug repurposing offers promising strategies to improve tuberculosis treatment despite challenges.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
33 citations
,
August 1993 in “FEBS Letters” A new enzyme in rats may help regulate hair growth.
7 citations
,
January 2017 in “Dermatology Online Journal” TNF-inhibitor induced alopecia can be treated effectively with different therapies.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
60 citations
,
September 2023 in “Science” BTNL proteins help control inflammatory bowel disease by maintaining specific immune cells.
129 citations
,
January 2004 in “Journal of medicinal chemistry” Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
38 citations
,
July 2020 in “EMBO journal” SIRT7 protein is crucial for starting hair growth in mice.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
34 citations
,
July 2011 in “International journal of pharmaceutics” Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
January 2019 in “Columbia Academic Commons (Columbia University)” TRPV3 and TRPV6 channels change structure to regulate calcium and heat responses.
1 citations
,
December 2024 in “Journal of Orthopaedic Research®” Aromoline and DRD4 are potential targets for osteoarthritis treatment.
119 citations
,
June 2005 in “Journal of Molecular and Cellular Cardiology” Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.
8 citations
,
October 2021 in “Microbiology spectrum” Researchers identified five new potential targets for leishmaniasis treatment, suggesting repurposing existing drugs could be effective.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
16 citations
,
September 1999 in “Journal of Investigative Dermatology Symposium Proceedings”